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Abstract
Background: Very few data exist on risk factors for developing biofilm-forming Candida bloodstream infection (CBSI) or on
variables associated with the outcome of patients treated for this infection.
Methods and Findings: We identified 207 patients with CBSI, from whom 84 biofilm-forming and 123 non biofilm-forming
Candida isolates were recovered. A case-case-control study to identify risk factors and a cohort study to analyze outcomes
were conducted. In addition, two sub-groups of case patients were analyzed after matching for age, sex, APACHE III score,
and receipt of adequate antifungal therapy. Independent predictors of biofilm-forming CBSI were presence of central
venous catheter (odds ratio [OR], 6.44; 95% confidence interval [95% CI], 3.21–12.92) or urinary catheter (OR, 2.40; 95% CI,
1.18–4.91), use of total parenteral nutrition (OR, 5.21; 95% CI, 2.59–10.48), and diabetes mellitus (OR, 4.47; 95% CI, 2.03–9.83).
Hospital mortality, post-CBSI hospital length of stay (LOS) (calculated only among survivors), and costs of antifungal therapy
were significantly greater among patients infected by biofilm-forming isolates than those infected by non-biofilm-forming
isolates. Among biofilm-forming CBSI patients receiving adequate antifungal therapy, those treated with highly active anti-
biofilm (HAAB) agents (e.g., caspofungin) had significantly shorter post-CBSI hospital LOS than those treated with non-HAAB
antifungal agents (e.g., fluconazole); this difference was confirmed when this analysis was conducted only among survivors.
After matching, all the outcomes were still favorable for patients with non-biofilm-forming CBSI. Furthermore, the biofilm-
forming CBSI was significantly associated with a matched excess risk for hospital death of 1.77 compared to non-biofilm-
forming CBSI.
Conclusions: Our data show that biofilm growth by Candida has an adverse impact on clinical and economic outcomes of
CBSI. Of note, better outcomes were seen for those CBSI patients who received HAAB antifungal therapy.
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Introduction
Candida bloodstream infections (CBSIs) are the fourth most
common infections among hospitalized patients [1], accounting
for 8% to 15% of hospital-acquired BSIs [2]. They are considered
high-morbidity infections [3,4], with significant hospital costs
[5,6], largely due to increased hospital length of stay (LOS) and
costs for antifungal therapy [2]. The excess of hospital stay
attributable to invasive Candida infections has been reported to
range from 10 to 30 days in the United States [2], and it could
have been underestimated because of the early mortality
associated with delayed therapy [7,8]. Recently, inappropriate
antifungal treatment resulted in prolonged hospital LOS and
increased hospital costs [9].
Candidemia is frequently associated with the biofilm growth of
Candida organisms on medical devices such as a venous catheter or
urinary catheter [10,11]. This infection is greatly serious because
biofilms are thought to be recalcitrant to antifungal (e.g.,
fluconazole) therapy [12], and only two classes of agents (i.e.,
amphotericin B and echinocandins) appear to have in vitro
efficacy against Candida biofilms [13,14].
A recent characterization of the ‘‘biofilm dispersal’’ phenome-
non demonstrated that the dispersed cells have several virulence
traits, distinct from planktonic cells [15]. Accordingly, formation of
biofilm by Candida bloodstream isolates has been associated with
increased virulence and mortality [16–19]. In this context, we
previously showed that inadequate antifungal therapy, infection
caused by biofilm-forming Candida isolates, and high Acute
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were independent predictors of mortality [18].
In the present study, we sought to determine risk factors for
CBSI caused by biofilm-forming isolates and the impact of this
infection on health and economic outcomes in adult patients.
Methods
Ethics Statement
The local institutional review committee approved the study,
and informed consent was not required because of the observa-
tional nature of this study.
Study Population and Design
We included all patients $18 years of age with culture-proven
CBSI who were hospitalized during the period from 2005 through
2007 at the Catholic University Hospital in Rome, Italy, which is
an academic tertiary care center with 1,500 beds and ,50,000
hospital admissions per year. All patients were identified by
electronically querying the clinical microbiology laboratory
database. Some of these patients have been described elsewhere
[20]. CBSI was defined as presence of $1 blood cultures growing
Candida species. Only the first episode of CBSI was reported for
patients with recurrent or subsequent episodes of infection.
Patients whose cultures grew .1 documented species of Candida
were excluded from analysis. Unless otherwise noted, the term
‘‘infection’’ refers to episode of candidemia under study.
This was a retrospective study consisting of two parts. For the
case-case-control study, two groups of CBSI patients, one with
infection caused by a biofilm-forming isolate and the other with
infection caused by a non-biofilm-forming isolate, were compared
with a common control group, consisting of randomly selected
patients who had been hospitalized in our center during the same
periods of time and in the same wards as the case patients, but who
did not have evidence of CBSI [20]. Patients were included only if
complete data series could be retrieved from their medical charts.
For the cohort study, patients with biofilm-forming CBSI were
compared to those with non-biofilm-forming CBSI. Additionally,
patients with biofilm-forming CBSI were matched to patients with
non-biofilm-forming CBSI for the following factors: age (610
years), sex, APACHE III score (63), and receipt of adequate
antifungal therapy [18]. If one patient could be matched to two or
more patients, then the patient with the closest APACHE III score
was selected.
Variables and Definitions
Data were extracted from the patients’ hospital records by using
a standardized case report form and included demographics (age,
sex); microbiological parameters (Candida species type, antifungal
susceptibility profile, biofilm formation test result); comorbid
conditions (diabetes mellitus, chronic obstructive pulmonary
disease [COPD], chronic renal failure, solid organ cancer,
hematologic malignancy, liver disease, human immunodeficiency
virus [HIV] infection, neutropenia [absolute neutrophil count,
,500 cells/mm
3]); the Charlson’s score was used as a composite
index of comorbidities; invasive procedures (including insertion of
a central venous catheter [CVC] or nasogastric tube, and urinary
catheterization), and total parenteral nutrition (TPN) administra-
tion within 72 h prior to the onset of CBSI; use of immunosup-
pressive agents, surgery, bacteremia, or exposure to antibiotics
within 30 days of the onset of candidemia (or, for controls, at any
point during hospitalization) [20]; time at risk, i.e., number of
hospital days from admission to the date of the first positive (index)
blood culture for case patients or total days in the hospital for
control patients [20]; antifungal therapy; and outcome parameters
(hospital LOS following the onset of CBSI [post-CBSI hospital
LOS], initial response to antifungal treatment, costs of antifungal
therapy, hospital mortality [i.e., death within 30 days of the first
documented CBSI episode], and infection-related mortality [i.e.,
mortality where the symptoms and signs of infection had not
resolved at the time of death and there was no alternative cause of
death]).
According to the European Center for Disease Prevention and
Control guidelines [21], CBSI was defined as health care-
associated if it occurred more than 48 h after admission to the
hospital and if no signs or symptoms of infection were noted at the
admission. For all cases, CBSI was considered to be catheter-
related if quantitative roll-plate cultures of the catheter tip yielded
more than 15 cfu of the same Candida species that was isolated
from the bloodstream or if simultaneous quantitative cultures
showed a ratio of $5:1 in cfu of blood samples obtained through
the catheter and a peripheral vein, or CBSI was considered to be
catheter-associated if it occurred in a patient with an intravascular
line in place at the time of, or within 48 h before, the onset of the
infection [22]. The time of onset of CBSI was defined as the date
in which the index culture for Candida was identified.
Adequate antifungal therapy was defined as the initiation of
antifungal therapy given at a recommended dosage within 24 h
after the index blood culture was obtained [23], with isolation of
an organism that was found to be susceptible in vitro (see below) to
the antifungal agent used.
Microbiology
For Candida blood isolates, species identification was performed
by micromorphology analysis and biochemical tests (Vitek 2 Yeast
Identification, bioMe ´rieux), whereas the antifungal susceptibility
testing of planktonic cells was determined by broth microdilution
method according to the Clinical and Laboratory Standards
Institute M27-A3 document [24]. For the same isolates, biofilm
formation was performed in batches using a known 96-well plate-
based method [25], with slight modifications. Briefly, each well of
polystyrene microtiter plates was inoculated with a Candida cell
suspension consisting of 3610
7 cfu/mL in Sabouraud dextrose
broth containing 8% glucose. After 24 h of incubation, planktonic
cells were discarded by washing the wells three times manually
with 0.15 M phosphate-buffered saline (PBS), and the remaining
cells adherent to the plastic surface (biofilm) were quantified by i) a
tetrazolium XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide] reduction assay and ii) direct absor-
bance measurement, as described previously [18]. In the first
method, a 100-ml aliquot of the XTT salt solution (Sigma; 1 mg/
mL in PBS) and 1 mM menadione solution (Sigma; prepared in
acetone) were added to each prewashed biofilm and to control
wells (for measurement of background XTT reduction levels). The
plates were incubated in the dark at 37uC for 5 h, and the amount
of XTT formazan was measured in a microtiter plate reader
(microplate reader model 550; Bio-Rad) at 490 nm. Isolates for
which the optical density was of ,0.1 were scored as non-biofilm
formers. In the second method, 200 ml of PBS was added to each
well and biofilm was measured directly by spectrophotometric
readings at 405 nm with the microtiter plate reader. The percent
transmittance (%T) was calculated by subtracting the %T value for
each test sample from the %T value for the reagent blank to obtain
a measure of the amount of light blocked passing through the wells
(%Tbloc). On the basis of %Tbloc values, biofilm formation by each
isolate was scored as either negative (%Tbloc, ,10) or positive
(%Tbloc, $10), according to which isolates were classified as non-
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SC5314 was used as a control strain in each experiment.
Statistical analysis
Following data collection, normally distributed continuous
variables were reported as mean 6 standard deviation (SD) and
compared using Student’s t test. Medians with ranges were used to
describe nonnormally distributed continuous variables, and
compared using the Mann-Whitney U-test. Categorical variables
were reported as percentages and compared using the two-tailed
x
2 test or Fisher’s exact test, as appropriate. After univariate
statistics were generated, all variables with a p-value of ,0.20 were
considered for inclusion in the multivariate logistic regression
model to identify independent risk factors for the development of
biofilm-related CBSI. We constructed a receiver operating curve
(ROC) to assess the validity of the model. In the matched cohort
study, comparisons of paired baseline characteristics were
performed using the paired Student’s t test and the McNemar
test for continuous and categorical variables, respectively. The
matched risk ratio and excess risk were expressed by ratio and
difference in mortality rates between exposed and unexposed
patients, respectively. Survival distribution function was estimated
using the Kaplan-Meier product-limit method; nonparametric
(log-rank and Wilcoxon) tests were used to compare the survival
functions among the different groups. All p-values were two-tailed
and statistical significance was defined as a p,0.05. Statistical
analyses were performed using Stata, version IC 11.
Results
During the study period, we identified a total of 222 case
patients with CBSI. Fifteen patients, from whom blood cultures
grew .1 species of Candida, were not included in the study. C.
albicans was most commonly isolated (58.9%, 122 patients),
whereas the majority of the other Candida species isolated included
C. parapsilosis (22.7%, 47 patients), Candida tropicalis (9.6%, 20
patients), and Candida glabrata (5.3%, 11 patients). Other species
(i.e., Candida krusei, Candida lusitaniae, and Candida guilliermondii)
accounted for the remaining 3.4% of isolates (7 patients).
Microbiological Findings
Eighty four (40.5%) of 207 patients were infected by biofilm-
forming Candida isolates, of which 32 were C. albicans, 29 were C.
parapsilosis, 13 were C. tropicalis, 7 were C. glabrata, 2 were C. krusei,
and 1 was C. guilliermondii, as assessed by the XTT and %T assays
(see Methods). The levels of biofilm formation quantified by the
XTT reduction assay for the 84 Candida isolates ranged from 0.125
to 1.358 (median, 0.592), whereas the corresponding levels
determined by the %T assay ranged from 11 to 62 (median, 26)
(Table S1). Overall, biofilm production by C. albicans was
significantly less frequent (26.2%, 32 of 122 isolates) than non-C.
albicans species (61.1%, 52 of 85 isolates) (P,0.001). Among the
latter species, biofilm production was most frequently observed for
C. tropicalis (70.0%, 14 of 20 isolates), followed by C. glabrata
(63.6%, 7 of 11 isolates), and C. parapsilosis (61.7%, 29 of 47
isolates). All planktonically growing isolates were found to be
susceptible in vitro to amphotericin B, flucytosine, caspofungin,
and anidulafungin, and, except for fluconazole-resistant C. glabrata
(3 isolates) and C. krusei isolates, to azoles.
Patients Characteristics
The demographic and clinical characteristics of case (n=207)
and control (n=200) patients are shown in Table 1. At the time of
candidemia, 36 (17.4%) patients were in the ICU and 84 (40.6%)
patients had a surgical admission. In spite of 141 (68.1%) catheter-
associated infections, there were 68 (32.8%) CVC-related
candidemia cases (diagnosed by catheter cultures in 37 cases and
by differential quantitative blood cultures of $5:1 ratio in 31
cases). The primary source of infection was unknown for 96
(46.4%) patients. Of case patients, 170 (82.1%) received adequate
systemic antifungal therapy, with a median duration of 24 days
(range, 2–46 days). Fluconazole was most frequently used (96
patients, 56.5%), followed by caspofungin (41 patients, 24.1%),
lipid formulations of amphotericin B (21 patients, 12.3%), and
voriconazole (12 patients, 7.1%). In particular, azoles (mostly
fluconazole) were administered to 47 (55.9%) of 84 patients with
biofilm-forming CBSI, and to 49 (39.8%) of 123 patients with non-
biofilm-forming CBSI. Therapy was considered inadequate for 37
(17.9%) patients. Of these, 6 patients (fluconazole-treated) were
infected by fluconazole-resistant C. glabrata or C. krusei isolates; 31
patients received antifungal treatment after 48 h of the time that
the index blood culture was obtained. Catheter removal was part
of treatment in 129 (91.5%) of the 141 patients with catheter-
associated CBSI, and in 67 (98.5%) of the 68 patients with
catheter-related CBSI.
Univariate and Multivariate Analyses
The 84 patients with biofilm-forming CBSI and 123 patients
with non-biofilm-forming CBSI were more likely than control
patients to have longer time at risk (p=0.05 and p=0.01,
respectively) or hospital LOS (p,0.001), underlying condition
such as COPD (p,0.001) or solid organ cancer (p=0.02 and
p=0.01, respectively), or higher Charlson’s score (p,0.001); they
were more likely to have central venous catheterization (p,0.001),
urinary catheterization (p,0.001), total parenteral nutrition
(p,0.001), neutropenia (p,0.001 and p=0.01), prior bacteremia
(p,0.001), or previous exposure to surgery (p,0.001), corticoste-
roids (p=0.005 and p,0.001, respectively), or broad-spectrum
antibiotics (p,0.001) (Table 1). Patients with biofilm-forming
CBSI were more likely to have diabetes mellitus (p,0.001) or
hematologic malignancy (p=0.03), whereas patients with non-
biofilm-forming CBSI were more likely to have chronic renal
failure (p=0.004), HIV infection (p=0.02), or previous exposure
to immunosuppressive agents (p=0.03) (Table 1).
Table 2 displays the results from the multivariate logistic
regression analysis. Central venous catheter use (OR 6.44; 95% CI
3.21–12.92), total parenteral nutrition administration (OR 5.21;
95% CI 2.59–10.48), diabetes mellitus (OR 4.47; 95% CI 2.03–
9.83), and urinary catheter use (OR 2.40; 95% CI 1.18–4.91) were
significantly associated with CBSI caused by a biofilm-forming
isolate. Together with the administration of total parenteral
nutrition (OR 8.41; 95% CI 3.70–19.08) or the presence of a
central venous catheter (OR 5.73; 95% CI 2.55–12.84), prior
broad-spectrum antibiotic use (OR 4.48; 95% CI 1.55–12.93) and
previous surgery (OR 2.45; 95% CI 1.04–5.81) were instead
independent risk factors for CBSI caused by a non-biofilm-forming
isolate. The ROC AUCs for the two multivariate models were
0.96 and 0.95 for biofilm-forming and non-biofilm-forming CBSI,
respectively, indicating that the models have excellent predictive
power.
Outcomes
The hospital mortality was 51.2% (43 of 84 patients) in the
biofilm-forming CBSI group, compared with 31.7% (39 of 123
patients) in the non-biofilm-forming CBSI group (p=0.004), with
infection-related mortality rates of 44.1% (37 of 84 patients) and
27.6% (34 of 123 patients), respectively (p=0.01). Differences in
the 30-day survival distributions were found between the two
Biofilm Candida Infection and Outcomes
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33705groups by overall (p=0.004) (Figure 1), and when the biofilm-
forming CBSI group was stratified by therapy with highly active
anti-biofilm (HAAB; e.g., caspofungin) or non-HAAB (e.g.,
fluconazole) antifungal agents (p=0.05) (Figure 1). As shown in
Figure 2, the median (range) post-CBSI hospital LOS did not
significantly differ between biofilm-forming CBSI group (20 days
[3–189]) and non-biofilm-forming CBSI group (19 days [1–105])
(p=0.16), by considering all case patients; however, this difference
between the groups reached statistical significance when calculated
only among patients who survived (32 days [11–189] vs. 20.5 days
[4–105], respectively, p=0.004). Among patients with biofilm-
forming CBSI, the median post-CBSI hospital LOS was longer (32
[4–189] days) in the group receiving non-HAAB antifungal
therapy compared to the HAAB antifungal therapy group (15
[3–85] days) (p=0.006); also by considering only the survivors,
patients receiving non-HAAB antifungal therapy had longer post-
CBSI hospital LOS than those receiving HAAB antifungal therapy
(33.5 [14–188] days vs. 16 [10–89] days, p,0.001) (Figure 2). As
expected, the mean antifungal therapy cost was higher for patients
with biofilm-forming CBSI than those with non-biofilm-forming
CBSI (J 10,80466590 vs. 606763934, p=0.04).
Results of a Matched Cohort Study
Seventy three (86.9%) of 84 patients with CBSI caused by a
biofilm-forming isolate could be matched to 73 patients with CBSI
caused by a non-biofilm-forming isolate, based on age, sex,
APACHE III score, and adequateness of antifungal therapy. A
comparison of patient characteristics between the two groups is
presented in Table 3. Similarly to that presented above,
significantly higher hospital mortality, post-CBSI hospital LOS,
and antifungal therapy costs were observed in biofilm-forming
CBSI patients compared to non-biofilm-forming CBSI patients
(p=0.004, p=0.007, and p=0.02, respectively). Furthermore, the
biofilm-related infection was associated with a matched excess risk
for death in hospital of 23.3% (53.4% vs. 30.1%, p=0.004), and
the matched risk ratio was 1.77.
Discussion
In the present study, we identified two unique risk factors,
diabetes mellitus and urinary catheterization, that were specifically
associated with biofilm-forming CBSI. Diabetes mellitus has
previously been reported to be a general risk factor for Candida
infections [10]. Yet, glucose is thought to serve as the carbohydrate
energy source required by Candida for biofilm formation [26],
perhaps necessary to produce the polysaccharide matrix [27], in
which organized communities of yeast, hyphae, and pseudohy-
phae are enclosed [11]. Hence, it is plausible that a hyperglycemic
condition may favor adaptation of Candida organisms to a biofilm
Figure 1. Survival among patients with Candida bloodstream infection (CBSI) at 30 days. Patients were grouped according to the biofilm-
forming (BF) or non-biofilm-forming (NBF) Candida isolate (for all CBSIs), and according to receiving of highly active anti-biofilm (HAAB) or non-HAAB
antifungal therapy (for BF CBSIs only). P-values for statistically significant differences between the groups are shown.
doi:10.1371/journal.pone.0033705.g001
Table 2. Logistic regression analysis of risk factors for
candidemias by biofilm-forming (BF) and non-biofilm-forming
(NBF) isolates.
Variable OR (95% CI)
BF CBSI
CVC in place at time of positive blood culture 6.44 (3.21–12.92)
Total parenteral nutrition 5.21 (2.59–10.48)
Diabetes mellitus 4.47 (2.03–9.83)
Urinary catheter in place at time of positive blood
culture
2.40 (1.18–4.91)
NBF CBSI
Total parenteral nutrition 8.41 (3.70–19.08)
CVC in place at time of positive blood culture 5.73 (2.55–12.84)
Antibiotic therapy in previous 30 days 4.48 (1.55–12.93)
Surgery in previous 30 days 2.45 (1.04–5.81)
NOTE. CBSI, Candida bloodstream infection; CVC, central venous catheter.
doi:10.1371/journal.pone.0033705.t002
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33705lifestyle, and this should be consistent with enhanced pathogenic
potential of biofilm-forming C. albicans strains isolated from
patients with type 1 diabetes [28]. Catheter-associated urinary
tract infections result in increased institutional death rates [29],
and are frequently associated with the formation of biofilms on the
catheter surfaces [10,30]. Whilst Candida biofilms in vitro are
formed frequently in nutrient-rich laboratory media (i.e., contain-
ing up to 8% of dextrose [16,18]), it was yet shown that a synthetic
urine medium (i.e., use of an in vitro model mimicking an in vivo
biofilm on a urinary catheter) was able to support the biofilm
growth of Candida [31], making verisimilar the likelihood that
fungal cells may spread from the infected urinary catheter and
seed the bloodstream, thereby promoting systemic candidiasis
[32].
A wide range of biomaterials used in clinical practice are shown
to support colonization and biofilm formation by Candida species
[30], making device-related Candida infections relatively refractory
to medical therapy [10]. It has been reported that certain Candida
species in the presence of glucose-containing fluids or lipid
emulsion might produce ‘‘slime’’ (now commonly referred to as
biofilm), potentially explaining the increased proportion of CBSIs
among patients receiving parenteral nutrition [16,22,26]. Surpris-
ingly, we found that use of CVC and receipt of total parenteral
nutrition were independently associated with all CBSIs in our
patients. A possible explanation for this finding is that not all of our
candidemia episodes originated from a catheter, as ,50% of
CBSIs had unrecognized primary sources. Of note, 59 of 139
patients with no CVC-related CBSI were infected by biofilm-
forming isolates, supporting the notion that the adherence
properties of infecting organisms are important, but not the sole
pathogenic determinants of catheter-related Candida infection [22].
In addition, the finding that either biofilm producers (25 patients)
or non-biofilm producers (43 patients) were found in our patients
who have a CVC-related candidemia makes difficult to determine
the role played by biofilms in the pathogenesis of this infection. As
removal of CVC regarded almost the totality of our patients, it was
not possible to establish whether patients with biofilm-forming
CBSI benefited from this therapeutic decision more than patients
with non-biofilm-forming CBSI. Consistently, it also seems likely
that non-device-related infections, such as certain infections on
epithelial surfaces involve Candida biofilms [11].
Nonetheless, our main goal in this study was to evaluate the
effect of biofilm production on clinical (mortality and length of
stay) and economic (costs of antifungal therapy) outcomes of
patients with CBSI, in an attempt to support and extend (different
years are included in the present analysis) our previous findings
that, together with well-established factors (i.e., inadequate
antifungal therapy and high APACHE III score), infection with
overall biofilm-forming Candida species is an independent predictor
of mortality for patients with candidemia [18]. In particular, we
previously found that only infections caused by C. albicans and
Candida parapsilosis were associated with higher mortality rates,
Figure 2. Hospital length of stay (LOS) following the Candida bloodstream infection (CBSI) onset in all (white box-plots) or surviving
(grey box-plots) patients. Patients were grouped according to the biofilm-forming (BF) or non-biofilm-forming (NBF) Candida isolate (for all CBSIs),
and according to receiving of highly active anti-biofilm (HAAB) or non-HAAB antifungal therapy (for BF CBSIs only). Lines inside the boxes indicate the
median values, whereas upper and lower limits of the boxes and whiskers indicate the interquartile and total ranges, respectively. P-values for
statistically significant differences between the groups are shown.
doi:10.1371/journal.pone.0033705.g002
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important contributor to the virulence of C. albicans or enhance the
pathogenic potential of C. parapsilosis [18].
Here, we initially determined the attributable adverse effects of
biofilm formation on patient outcomes, by analyzing patients with
biofilm-forming CBSI who were substantially different from the
patients with non-biofilm-forming CBSI. Hence, to partially
eliminate the effects of intergroup differences on patient outcomes,
we have chosen to compare groups of matched patients who were
very similar for age, sex, APACHE III score, and receipt of
adequate antifungal treatment, but differed regarding the other
variable(s) of interest. We found that not only hospital mortality
Table 3. Comparison between patients with biofilm-forming (BF) candidemia or non-biofilm-forming (NBF) candidemia in the
matched cohort study.
Variable BF-CBSI group (n=73) NBF-CBSI group (n=73) P-value
Hospital LOS, days
a 40 (11–277) 35 (15–150) 0.21
ICU stay at diagnosis 9 (12.3) 11 (15.1) 0.63
Time at risk, days
b 20 (3–192) 15 (2–123) 0.41
Species isolated
Candida albicans 30 (41.1) 52 (71.2) ,0.001
Candida parapsilosis 24 (32.9) 10 (13.7) 0.006
Candida tropicalis 10 (13.7) 5 (6.8) 0.17
Candida glabrata 6 (8.2) 3 (4.1) 0.30
Other
c 3 (4.1) 3 (4.1) 1.00
Neutropenia
d 6 (8.2) 4 (5.5) 0.51
Comorbid conditions
COPD 16 (21.9) 16 (21.9) 1.00
Solid organ cancer 29 (39.7) 28 (38.3) 0.86
Hematologic cancer 7 (9.6) 6 (8.2) 0.77
Diabetes mellitus 28 (38.4) 10 (13.7) ,0.001
Chronic renal failure 17 (23.3) 18 (24.6) 0.84
Liver disease 9 (12.3) 7 (9.6) 0.59
HIV infection 1 (1.4) 1 (1.4) 1.00
Charlson’s score 3 (0–15) 3 (0–10) 0.58
Invasive procedures
CVC 48 (65.7) 52 (71.2) 0.47
Nasogastric tube 24 (32.9) 23 (31.5) 0.85
Urinary catheter 57 (78.1) 38 (52.1) ,0.001
Total parenteral nutrition 51 (69.9) 55 (75.3) 0.45
Previous bacteremia
e 20 (27.4) 18 (24.6) 0.70
Previous surgery 32 (43.8) 38 (52.1) 0.32
Prior use of:
corticosteroids 23 (31.5) 28 (38.3) 0.38
immunosuppressive agents 15 (20.5) 18 (24.6) 0.55
broad-spectrum antibiotics 66 (90.4) 67 (91.8) 0.77
Outcome parameters
Initial treatment failure
f 26 (35.6) 15 (20.5) 0.04
Hospital LOS after CBSI, days 29631 1965 0.007
Hospital mortality 39 (53.4) 22 (30.1) 0.004
Infection-related mortality 32 (43.8) 18 (24.6) 0.01
Antifungal therapy cost J 11,37166544 J 610864106 0.02
NOTE. Results are shown as no. (%) or median with range. LOS, length of stay; ICU, intensive care unit; CBSI, Candida bloodstream infection; COPD, chronic obstructive
pulmonary disease; HIV, human immunodeficiency virus; CVC, central venous catheter.
aDays of hospital stay prior to the onset of candidemia (or, for controls, total days in the hospital).
bNumber of hospital days from admission to the onset of candidemia (or, for controls, total days in the hospital).
cOther species includes Candida krusei (3 cases), Candida lusitaniae (2 cases), and Candida guilliermondii (1 case).
dAbsolute neutrophil count ,500 cells/mm
3.
eWithin 30 days prior to the onset of candidemia (or, for controls, at any point during hospitalization).
fTherapeutic failure at 72 h after starting antifungal therapy, as assessed by the persistence of infection or by the occurrence of death.
doi:10.1371/journal.pone.0033705.t003
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were significantly greater among patients infected by biofilm-
forming isolates than those of patients infected by non-biofilm-
forming isolates. Thus, we assessed (in absolute novelty with
respect to our previous study) whether the treatment with a HAAB
antifungal agent might significantly affect all the outcomes we
analyzed. In this context, a recent work suggested that the total
treatment cost of candidemia is strongly influenced by the choice
of initial antifungal treatment, that increases overall expenditure
largely creating a need for additional hospital days [33]. In our
study, 55.9% of patients treated for biofilm-forming CBSI were
treated with azole antifungals. As Figure 2 shows, the post-CBSI
hospital LOS was significantly longer in patients who received
non-HAAB antifungal therapy (e.g., fluconazole [34]), compared
to patients treated with a HAAB antifungal agent (e.g.,
echinocandins [14,34]). Noteworthy, by considering only patients
who survived, this difference favored again significantly the HAAB
antifungal treatment (Figure 2). As the choice of first-line
antifungal agent should take into account the actual possibility
of a biofilm-forming CBSI, our findings add support to the
growing evidence that echinocandin drugs may effectively act
against biofilm-related infections [35,36]. The management of
biofilm-forming Candida infections is greatly influenced by their
persistent nature and associated drug resistance [12], perhaps
because of the dispersion of ‘‘persister’’ antifungal-resistant biofilm
cells [15]. It is plausible that the excess of mortality we observed in
our matched patients could be attributed to the difficulty to
prevent complete eradication of organisms from the blood or to
eliminate a potential nidus of infection that may perpetuate
seeding of the bloodstream.
The main limitations of the present study were the retrospective
design which may have predisposed it to a selection bias, and the
single-center nature which may limit the results’ generalization to
other centers.
In conclusion, our data expand current knowledge of the impact
of hospital-acquired CBSI on the patients’ survival, and point out
the major risk factors for biofilm-related candidemia. Also, we
shed light on the potential cost and hospital resource savings that
may be possible if biofilm-forming CBSIs would be promptly
treated with more effective antifungal agents.
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